$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
FDA approves u200c Lurbinectedin for the treatment of metastatic small cell lung cancer
2025-10-19 11:44:20
Check Details
Usage and dosage of Lurbinectedin: recommended dose, dose adjustment
2025-10-19 11:44:20
Check Details
Side effects and common adverse reactions of Lurbinectedin
2025-10-19 11:44:20
Check Details
Detailed instructions for Lurbinectedin: indications, usage and dosage, side effects and precautions
2025-10-19 11:44:20
Check Details
Chinese instructions for rubidine (Zepzelca)
2025-10-19 11:44:20
Check Details
Detailed instructions for Durvalumab: indications, usage and dosage, side effects and precautions
2025-10-19 11:44:20
Check Details
Tarlatamab FDA Approved for Treatment of Extensive Stage Small Cell Lung Cancer
2025-10-19 11:44:20
Check Details
Tarlatamab usage and dosage: recommended dosage, special populations and delayed dosing dosage adjustments
2025-10-19 11:44:20
Check Details
Side effects and common adverse reactions of Tarlatamab
2025-10-19 11:44:20
Check Details
Detailed instructions for Tarlatamab
2025-10-19 11:44:20
Check Details
Tarlatamab (Tarlatamab) Chinese instruction manual: indications, usage and dosage, adverse reactions, precautions
2025-10-19 11:44:20
Check Details
How to alleviate the side effects of Ripotinib
2025-10-19 11:44:20
Check Details
1
2
...
10229
10230
10231
10232
10233
10234
10235
10236
10237
10238
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Vosoritide Side Effects and Pre-Injection Food/Fluid: Injection-Site Reactions, Transient Hypotension
2
Ribociclib Still Allows Recurrence: HR+/HER2- Adjuvant and Advanced Use
3
Pretomanid Mechanism and BPaL Use in Drug-Resistant TB
4
Pacritinib Drug Contraindications and Precautions
5
Pomalidomide Side Effects, Risk Monitoring, and Precautions
6
Dasatinib for Ph+ Chronic Myeloid Leukemia: Dosage, Administration, and Long-Term Care
7
Obeticholic Acid 5 mg for PBC: Dosage, Risks, and Current Status
8
Acalabrutinib Monotherapy for CLL: What It Can and Cannot Do
9
Bepirovirsen for Chronic HBV Functional Cure: FDA Criteria and B-Well Data
10
After Ibrutinib Resistance: CLL/SLL and MCL Next Steps, Progression vs Intolerance
11
Tucatinib HER2 TKI: With Trastuzumab + Capecitabine, Diarrhea and Hepatotoxicity Monitoring
12
Quizartinib for FLT3-ITD AML: Induction-Consolidation-Maintenance and QT Monitoring